← Eichor
Condition: Metastatic Castration Resistant Prostate Adenocarcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Metastatic Castration Resistant Prostate Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Phase N/A · 3 location(s) · Duke University · NCT06141993A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Phase 1 · 8 location(s) · Bristol-Myers Squibb · NCT06067841Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 8 location(s) · Acerand Therapeutics (Hong Kong) Limited · NCT06801236The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
Phase 2 · 2 location(s) · University Medical Center Groningen · NCT07038304Imaging of Solid Tumors Using 18F-TRX
Phase 1 · 1 location(s) · Rahul Aggarwal · NCT06942104A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Phase 1 · 6 location(s) · Deciphera Pharmaceuticals, LLC · NCT06966024Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Phase 2 · 31 location(s) · Dendreon · NCT06134232Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
Phase 1 · 1 location(s) · Beijing Biotech · NCT07641049Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) a
Phase 2 · 1 location(s) · Tianjin Medical University Second Hospital · NCT07179783Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME T
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT04693377Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)
Phase 2 · 12 location(s) · Fundacion Oncosur · NCT06582628177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07219147Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06145633Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 107 location(s) · DualityBio Inc. · NCT05914116Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06236139A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for A
Phase 1/Phase 2 · 24 location(s) · Regeneron Pharmaceuticals · NCT03972657FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 33 location(s) · Parabilis Medicines, Inc. · NCT05919264Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer
Phase N/A · 1 location(s) · Kuopio University Hospital · NCT06850545Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Adva
Phase 3 · 102 location(s) · Alliance for Clinical Trials in Oncology · NCT07200830Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase 1/Phase 2 · 3 location(s) · University of Michigan Rogel Cancer Center · NCT06616155A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resist
Phase 1 · 6 location(s) · Daiichi Sankyo · NCT07189403Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 2 · 2 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT04704505Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase 2 · 1 location(s) · University of Utah · NCT05168618Castrate Resistant Prostate Cancer Enhertu Therapy
Phase 2 · 1 location(s) · Washington D.C. Veterans Affairs Medical Center · NCT06610825Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA St
Phase 2 · 1 location(s) · University of Washington · NCT06039371Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Phase 1/Phase 2 · 1 location(s) · Vadim S Koshkin · NCT05113537A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abirater
Phase 2 · 7 location(s) · Prostate Cancer Clinical Trials Consortium · NCT06844383
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.